Intrinsic indicators for specimen degradation

被引:8
作者
Li, Jie [1 ]
Kil, Catherine [1 ]
Considine, Kelly [1 ]
Smarkucki, Bartosz [1 ]
Stankewich, Michael C. [1 ]
Balgley, Brian [2 ]
Vortmeyer, Alexander O. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA
[2] Bioproximity LLC, Springfield, VA USA
关键词
alpha-II spectrin; degradation; indicator; proteomics; specimen; PROTEIN PHOSPHATASE 2A; BETA-II-SPECTRIN; ALPHA-II; MEMBRANE-PROTEINS; CELL-DEATH; CALPAIN; COMPLEX; DECOMPOSITION; CASPASE; ACTIN;
D O I
10.1038/labinvest.2012.164
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Variable degrees of molecular degradation occur in human surgical specimens before clinical examination and severely affect analytical results. We therefore initiated an investigation to identify protein markers for tissue degradation assessment. We exposed 4 cell lines and 64 surgical/autopsy specimens to defined periods of time at room temperature before procurement (experimental cold ischemic time (CIT)-dependent tissue degradation model). Using two-dimensional fluorescence difference gel electrophoresis in conjunction with mass spectrometry, we performed comparative proteomic analyses on cells at different CIT exposures and identified proteins with CIT-dependent changes. The results were validated by testing clinical specimens with western blot analysis. We identified 26 proteins that underwent dynamic changes (characterized by continuous quantitative changes, isoelectric changes, and/or proteolytic cleavages) in our degradation model. These changes are strongly associated with the length of CIT. We demonstrate these proteins to represent universal tissue degradation indicators (TDIs) in clinical specimens. We also devised and implemented a unique degradation measure by calculating the quantitative ratio between TDIs' intact forms and their respective degradation-modified products. For the first time, we have identified protein TDIs for quantitative measurement of specimen degradation. Implementing these indicators may yield a potentially transformative platform dedicated to quality control in clinical specimen analyses. Laboratory Investigation (2013) 93, 242-253; doi:10.1038/labinvest.2012.164; published online 19 November 2012
引用
收藏
页码:242 / 253
页数:12
相关论文
共 67 条
[1]   Analytic Variability in Immunohistochemistry Biomarker Studies [J].
Anagnostou, Valsamo K. ;
Welsh, Allison W. ;
Giltnane, Jennifer M. ;
Siddiqui, Summar ;
Liceaga, Camil ;
Gustavson, Mark ;
Syrigos, Konstantinos N. ;
Reiter, Jill L. ;
Rimm, David L. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (04) :982-991
[2]   Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables [J].
Bai, Yalai ;
Tolles, Juliana ;
Cheng, Huan ;
Siddiqui, Summar ;
Gopinath, Arun ;
Pectasides, Eirini ;
Camp, Robert L. ;
Rimm, David L. ;
Molinaro, Annette M. .
LABORATORY INVESTIGATION, 2011, 91 (08) :1253-1261
[3]   HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods [J].
Bartlett, J. M. S. ;
Starczynski, J. ;
Atkey, Neil ;
Kay, E. ;
O'Grady, A. ;
Gandy, Michael ;
Ibrahim, Merdol ;
Jasani, Bharat ;
Ellis, I. O. ;
Pinder, S. E. ;
Walker, R. A. .
JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (08) :649-653
[4]   Spectrin and ankyrin-based pathways: Metazoan inventions for integrating cells into tissues [J].
Bennett, V ;
Baines, AJ .
PHYSIOLOGICAL REVIEWS, 2001, 81 (03) :1353-1392
[5]   Regulation of stress-induced intracellular sorting and chaperone function of Hsp27 (HspB1) in mammalian cells [J].
Bryantsev, Anton L. ;
Kurchashova, Svetlana Yu. ;
Golyshev, Sergey A. ;
Polyakov, Vladimir Yu. ;
Wunderink, Herman F. ;
Kanon, Bart ;
Budagova, Karina R. ;
Kabakov, Alexander E. ;
Kampinga, Harm H. .
BIOCHEMICAL JOURNAL, 2007, 407 (407-417) :407-417
[6]   Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J].
Cappuzzo, F ;
Magrini, E ;
Ceresoli, GL ;
Bartolini, S ;
Rossi, E ;
Ludovini, V ;
Gregorc, V ;
Ligorio, C ;
Cancellieri, A ;
Damiani, S ;
Spreafico, A ;
Paties, CT ;
Lombardo, L ;
Calandri, C ;
Bellezza, G ;
Tonato, M ;
Crinò, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1133-1141
[7]  
Cardali S, 2006, J Neurosurg Sci, V50, P25
[8]   Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer [J].
Chang, John Wen-Cheng ;
Chou, Chun-Liang ;
Huang, Shiu-Feng ;
Wang, Hung-Ming ;
Hsieh, Jia-Juan ;
Hsu, Todd ;
Cheung, Yun-Chung .
LUNG CANCER, 2007, 58 (03) :414-417
[9]  
Chin JL, 2012, CUAJ-CAN UROL ASSOC, V4, P13
[10]   HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEINS - ROLE IN RNA SPLICING [J].
CHOI, YD ;
GRABOWSKI, PJ ;
SHARP, PA ;
DREYFUSS, G .
SCIENCE, 1986, 231 (4745) :1534-1539